跳至主要内容
临床试验/NCT07583823
NCT07583823招募中不适用

Elevated Rate Pacing of Cardiac Amyloidosis

University of Minnesota1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2025年10月10日最近更新:

试验速览

阶段
不适用
状态
招募中
入组人数
10
试验地点
1

研究概览

简要总结

This study aims to better quantify the improvements in heart failure symptoms and exercise tolerance before and after the heart rate elevation in a cohort of 10 cardiac amyloidosis patients with preexisting pacemakers.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Supportive Care
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adults 18 and older
  • Diagnosis of cardiac amyloidosis as indicated by the criteria set forth in guidelines such as in Kittleson et al: "2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis: A Report of the American College of Cardiology Solution Set Oversight Committee
  • Implanted Cardiac Pacemaker (+/- Defibrillator)
  • Pacemaker mode of AAI or DDD if in sinus rhythm, VVI acceptable if permanent atrial fibrillation
  • Non-dilated left ventricle by echocardiography
  • Ability to provide written consent
  • English Speaking

排除标准

  • Paced QRS duration of >150 ms (indicator for pacing mediated dyssynchrony)
  • Dilated left ventricle

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验